Active ingredientAsciminibCat. No. P-A194-001CAS 1492952-76-7Family · Pharmaceutical analytical standards
Asciminib
An oral cancer medicine for Philadelphia chromosome-positive chronic myeloid leukaemia, approved in the United States in 2021 and in the European Union in 2022; it blocks the BCR-ABL protein at a different site from classic inhibitors. This family brings together the active ingredient, metabolites and other impurities.
Did you know?It slots into the 'myristoyl pocket', where in the normal ABL protein a fatty acid chain docks and acts as a brake: in this way it restores a natural switch that the cancer protein has lost.
Go to the active ingredient →Active ingredientAsciminibCat. No. P-A194-001CAS 1492952-76-7
MetaboliteAsciminib O-Glucuronide HClCat. No. P-A194-002
Impurity(S)-AsciminibCat. No. P-A194-003CAS 1492952-73-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.